Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an update.
MindBio Therapeutics Corp. has acquired Life AI Corp. Pty. Ltd., a company with technology for alcohol intoxication detection through a smartphone app. This acquisition is expected to enhance MindBio’s capabilities in speech analysis for medication adherence and open commercial opportunities in alcohol and drug testing using voice analysis. The acquisition aligns with MindBio’s strategic goals and does not constitute a fundamental change or alter control of the company.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a biotech/biopharmaceutical company focused on developing novel treatments for mental health conditions. It is a leader in psychedelic microdosing and is conducting pioneering take-home microdosing clinical trials. The company is advancing its drug and technology protocols through clinical trials and is involved in psychedelic medicine development and digital therapeutics.
YTD Price Performance: -25.00%
Average Trading Volume: 83,871
Technical Sentiment Signal: Buy
Learn more about MBIO stock on TipRanks’ Stock Analysis page.